help button home button
AJRCMB
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miotla, J. M.
Right arrow Articles by Hellewell, P. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miotla, J. M.
Right arrow Articles by Hellewell, P. G.

Am. J. Respir. Cell Mol. Biol., Volume 18, Number 3, March, 1998 411-420

Suppression of Acute Lung Injury in Mice by an Inhibitor of Phosphodiesterase Type 4 

Jadwiga M. Miotla, Mauro M. Teixeira, and Paul G. Hellewell

Applied Pharmacology, Imperial College School of Medicine, National Heart and Lung Institute, London, United Kingdom

The present study has investigated the therapeutic potential of a type 4 phosphodiesterase (PDE) inhibitor, rolipram, in experimental lung injury. Acute lung injury was induced in the mouse by combined treatment with lipopolysaccharide (LPS; 10 mg/kg, i.v.) and zymosan (3 mg/kg, i.v.), and assessed using extravascular albumin accumulation; neutrophil sequestration in pulmonary capillaries was also measured. The results show that pretreatment with rolipram (5 mg/kg, i.p.) was protective against the induction of lung injury by combined LPS and zymosan; extravascular albumin accumulation was reduced by 89% and neutrophil sequestration in lung tissue, as assessed by lung myeloperoxidase (MPO) activity was reduced by 75%. Pretreatment with rolipram also attenuated increases in serum tumor necrosis factor alpha (TNFalpha ) levels induced by LPS and zymosan treatment, measured after 2.5 h. The role of endogenous TNFalpha in the induction of lung injury was therefore assessed. Blockade of endogenous TNFalpha by treatment with the soluble receptor p55-IgG fusion protein or an anti-murine TNFalpha monoclonal antibody, TN3.19.12, had no protective effect against LPS and zymosan-induced lung injury. This suggests that there is a disassociation between TNFalpha production and the induction of injury in this model. Administration of rolipram after LPS and before zymosan treatment obliterated the increase in pulmonary vascular permeability, but its effect on sequestration of neutrophils in pulmonary microvessels, as measured by MPO, was less marked. The results of the present study suggest that use of agents such as rolipram that inhibit PDE4 may have a therapeutic role in treatment of acute lung injury, since we have shown that it is effective in attenuation of neutrophil activation even after sequestration. However, its effect appears to be independent of TNFalpha inhibition.




This article has been cited by other articles:


Home page
 FASEB J.Home page
L. De Franceschi, O. S. Platt, G. Malpeli, A. Janin, A. Scarpa, C. Leboeuf, Y. Beuzard, E. Payen, and C. Brugnara
Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice
FASEB J, June 1, 2008; 22(6): 1849 - 1860.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Biol.Home page
B. D. Sachs, G. S. Baillie, J. R. McCall, M. A. Passino, C. Schachtrup, D. A. Wallace, A. J. Dunlop, K. F. MacKenzie, E. Klussmann, M. J. Lynch, et al.
p75 neurotrophin receptor regulates tissue fibrosis through inhibition of plasminogen activation via a PDE4/cAMP/PKA pathway
J. Cell Biol., July 30, 2007; 177(6): 1119 - 1132.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. McCluskie, U. Klein, C. Linnevers, Y.-h. Ji, A. Yang, C. Husfeld, and G. R. Thomas
Phosphodiesterase Type 4 Inhibitors Cause Proinflammatory Effects in Vivo
J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 468 - 476.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
G. N. Dietsch, C. R. Dipalma, R. J. Eyre, T. Q. Pham, K. M. Poole, N. B. Pefaur, W. D. Welch, E. Trueblood, W. D. Kerns, and S. T. Kanaly
Characterization of the Inflammatory Response to a Highly Selective PDE4 Inhibitor in the Rat and the Identification of Biomarkers that Correlate with Toxicity
Toxicol Pathol, January 1, 2006; 34(1): 39 - 51.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Seybold, D. Thomas, M. Witzenrath, S. Boral, A. C. Hocke, A. Burger, A. Hatzelmann, H. Tenor, C. Schudt, M. Krull, et al.
Tumor necrosis factor-{alpha}-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability
Blood, May 1, 2005; 105(9): 3569 - 3576.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
T.-L. Hwang, H.-W. Hung, S.-H. Kao, C.-M. Teng, C.-C. Wu, and S. J.-S. Cheng
Soluble Guanylyl Cyclase Activator YC-1 Inhibits Human Neutrophil Functions through a cGMP-Independent but cAMP-Dependent Pathway
Mol. Pharmacol., December 1, 2003; 64(6): 1419 - 1427.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
P.R.M. Rocco, D.P. Momesso, R.C. Figueira, H.C. Ferreira, R.A. Cadete, A. Legora-Machado, V.L.G. Koatz, L.M. Lima, E.J. Barreiro, and W.A. Zin
Therapeutic potential of a new phosphodiesterase inhibitor in acute lung injury
Eur. Respir. J., July 1, 2003; 22(1): 20 - 27.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
D. G. Souza, A. C. Soares, V. Pinho, H. Torloni, L. F. L. Reis, M. T. Martins, and A. A. M. Dias
Increased Mortality and Inflammation in Tumor Necrosis Factor-Stimulated Gene-14 Transgenic Mice after Ischemia and Reperfusion Injury
Am. J. Pathol., May 1, 2002; 160(5): 1755 - 1765.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Corbel, N. Germain, J. Lanchou, S. Molet, P. M. R. e Silva, M. A. Martins, E. Boichot, and V. Lagente
The Selective Phosphodiesterase 4 Inhibitor RP 73-401 Reduced Matrix Metalloproteinase 9 Activity and Transforming Growth Factor-beta Release During Acute Lung Injury in Mice: The Role of the Balance Between Tumor Necrosis Factor-alpha and Interleukin-10
J. Pharmacol. Exp. Ther., April 1, 2002; 301(1): 258 - 265.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
K. Nishina, K. Mikawa, O. Morikawa, H. Obara, and R. J. Mason
The Effects of Intravenous Anesthetics and Lidocaine on Proliferation of Cultured Type II Pneumocytes and Lung Fibroblasts
Anesth. Analg., February 1, 2002; 94(2): 385 - 388.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
A. KANEHIRO, T. IKEMURA, M. J. MÄKELÄ, M. LAHN, A. JOETHAM, A. DAKHAMA, and E. W. GELFAND
Inhibition of Phosphodiesterase 4 Attenuates Airway Hyperresponsiveness and Airway Inflammation in a Model of Secondary Allergen Challenge
Am. J. Respir. Crit. Care Med., January 1, 2001; 163(1): 173 - 184.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. Ikemura, J. Schwarze, M. Makela, A. Kanehiro, A. Joetham, K. Ohmori, and E. W. Gelfand
Type 4 Phosphodiesterase Inhibitors Attenuate Respiratory Syncytial Virus-Induced Airway Hyper-Responsiveness and Lung Eosinophilia
J. Pharmacol. Exp. Ther., August 1, 2000; 294(2): 701 - 706.
[Abstract] [Full Text]

Home page
 Am. J. Pathol.Home page
N. Diaz-Granados, K. Howe, J. Lu, and D. M. McKay
Dextran Sulfate Sodium-Induced Colonic Histopathology, but not Altered Epithelial Ion Transport, Is Reduced by Inhibition of Phosphodiesterase Activity
Am. J. Pathol., June 1, 2000; 156(6): 2169 - 2177.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
D. HÄFNER and P.-G. GERMANN
Additive Effects of Phosphodiesterase-4 Inhibition on Effects of rSP-C Surfactant
Am. J. Respir. Crit. Care Med., May 1, 2000; 161(5): 1495 - 1500.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. T. Schermuly, A. Roehl, N. Weissmann, H. A. Ghofrani, C. Schudt, H. Tenor, F. Grimminger, W. Seeger, and D. Walmrath
Subthreshold Doses of Specific Phosphodiesterase Type 3 and 4 Inhibitors Enhance the Pulmonary Vasodilatory Response to Nebulized Prostacyclin with Improvement in Gas Exchange
J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 512 - 520.
[Abstract] [Full Text]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
Y. Sato, S. Sato, T. Yamamoto, S. Ishikawa, M. Onizuka, and Y. Sakakibara
Phosphodiesterase type 4 inhibitor reduces the retention of polymorphonuclear leukocytes in the lung
Am J Physiol Lung Cell Mol Physiol, June 1, 2002; 282(6): L1376 - L1381.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Crit. Care Med.
Copyright © 1998 American Thoracic Society.